Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 3/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 8/20 | 0.35 |
| ▸ | CNR1 | P21554 | 6/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.34 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.34 |
| ▸ | FPR2 | P25090 | 1/20 | 0.34 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5039357 | 0.83 | CRHR1 (0.38) | CRHR1OPRM1CNR2CNR1TDP1 | |
| SCHEMBL5039336 | 0.82 | CRHR1 (0.42) | CRHR1OPRM1CNR2CNR1TDP1 | |
| SCHEMBL5048476 | 0.82 | CRHR1 (0.38) | CRHR1OPRM1CNR2CNR1CACNA2D1 | |
| SCHEMBL5048463 | 0.81 | LMNA (0.38) | CRHR1OPRM1CNR2CNR1CACNA2D1 | |
| SCHEMBL5039224 | 0.81 | CRHR1 (0.37) | CRHR1OPRM1CNR2CNR1CACNA2D1 | |
| SCHEMBL5044922 | 0.81 | CRHR1 (0.38) | CRHR1OPRM1CNR2CNR1CACNA2D1 | |
| SCHEMBL5044717 | 0.79 | CRHR1 (0.39) | CRHR1OPRM1FPR2PROKR1 | |
| SCHEMBL5044216 | 0.78 | CNR2 (0.38) | CRHR1CNR2CNR1 | |
| SCHEMBL5048815 | 0.78 | CRHR1 (0.36) | CRHR1OPRM1CNR2CNR1CACNA2D1 | |
| SCHEMBL5039786 | 0.78 | CRHR1 (0.36) | CRHR1OPRM1CNR2CNR1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432283-B2 | Heterocyclic GABAA subtype selective receptor modulators | ROCHE PALO ALTO LLC (US) | 2008-10-07 | — | — | US | disclosed |
| EP-1718299-A1 | HETEROCYCLIC GABA-A SUBTYPE SELECTIVE RECEPTOR MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-11-08 | — | — | EP | disclosed |
| US-20050197330-A1 | Heterocyclic GABAA subtype selective receptor modulators | ROCHE PALO ALTO LLC | 2005-09-08 | — | — | US | disclosed |
| WO-2005077363-A1 | HETEROCYCLIC GABA-A SUBTYPE SELECTIVE RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197330-A1 | Heterocyclic GABAA subtype selective receptor modulators | GABRA2, GABRA1, GABRA5 | CRHR1 71/4885OPRM1 61/4885ALDH1A1 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.